Assetmark Inc. Has $159.82 Million Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)

Key Points

• Assetmark Inc. increased its holdings in United Therapeutics Corporation by 20.8%, owning 518,450 shares worth approximately $159.82 million as of the latest filing.
• Insiders at United Therapeutics have sold a significant amount of stock recently, with Director Richard Giltner selling 3,036 shares for $879,226, marking a 13.54% reduction in his ownership.
• Equities analysts have mixed views on United Therapeutics, with some lowering their ratings and target prices while others maintain a "buy" rating, indicating fluctuating market sentiment.

Assetmark Inc. raised its stake in United Therapeutics Corporation (NASDAQ:UTHR - Free Report) by 20.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 518,450 shares of the biotechnology company's stock after purchasing an additional 89,290 shares during the quarter. Assetmark Inc. owned 1.15% of United Therapeutics worth $159,823,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Dunhill Financial LLC boosted its stake in shares of United Therapeutics by 100.0% in the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after buying an additional 50 shares in the last quarter. Sound Income Strategies LLC purchased a new stake in shares of United Therapeutics in the first quarter valued at approximately $49,000. State of Wyoming acquired a new position in United Therapeutics during the fourth quarter worth $62,000. Curat Global LLC purchased a new stake in United Therapeutics during the first quarter worth $63,000. Finally, Natixis acquired a new stake in United Therapeutics in the fourth quarter valued at $85,000. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other United Therapeutics news, Director Richard Giltner sold 3,036 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.60, for a total transaction of $879,225.60. Following the transaction, the director directly owned 19,384 shares in the company, valued at approximately $5,613,606.40. The trade was a 13.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Nilda Mesa sold 645 shares of the company's stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the transaction, the director directly owned 4,883 shares of the company's stock, valued at $1,416,021.17. This represents a 11.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 81,681 shares of company stock valued at $24,628,589. Insiders own 10.30% of the company's stock.

United Therapeutics Price Performance

Shares of NASDAQ UTHR traded down $1.91 during midday trading on Friday, hitting $304.50. The stock had a trading volume of 310,921 shares, compared to its average volume of 372,488. The company's 50-day simple moving average is $300.01 and its 200 day simple moving average is $316.20. The firm has a market cap of $13.74 billion, a P/E ratio of 12.15, a price-to-earnings-growth ratio of 6.68 and a beta of 0.53. United Therapeutics Corporation has a fifty-two week low of $266.98 and a fifty-two week high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts' consensus estimates of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The business had revenue of $794.40 million during the quarter, compared to analysts' expectations of $726.82 million. During the same period in the previous year, the firm earned $6.17 earnings per share. The firm's quarterly revenue was up 17.2% compared to the same quarter last year. Equities analysts expect that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the topic of several research reports. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. HC Wainwright reissued a "buy" rating and issued a $425.00 target price on shares of United Therapeutics in a report on Monday, May 5th. JPMorgan Chase & Co. lowered their target price on United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. UBS Group dropped their price objective on United Therapeutics from $410.00 to $385.00 and set a "buy" rating for the company in a research report on Monday, June 30th. Finally, Cantor Fitzgerald initiated coverage on United Therapeutics in a research report on Monday, June 2nd. They set an "overweight" rating and a $405.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to MarketBeat.com, United Therapeutics has an average rating of "Moderate Buy" and an average price target of $383.08.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.